Sequential thoracic metastasectomy prolongs survival by re-establishing local control within the chest  by Jaklitsch, Michael T. et al.
control of the primary site, no other distant metastatic
disease, a technically feasible operation, and adequate
cardiopulmonary reserve of the patient.1-3
Although no randomized trial has established a sur-
vival advantage of pulmonary metastasectomy,4 the
overall 30% 5-year survival is better than that of non-
surgical therapies.1-3 However, some authors argue that
the careful selection of these patients explains the long-
term survival and the value of pulmonary metastasecto-
my is unproven.5-7
The potential role for repeat metastasectomy has not
been as critically evaluated.2,3,8-10 In the report from the
International Registry of Lung Metastases, 53% of the
5206 cases had a recurrence after an initial pulmonary
metastasectomy.11 In those 1042 patients able to under-
Pulmonary metastasectomy, or the surgical removalof metastases to the lung, is now accepted as an
effective means of establishing local control in proper-
ly selected cases. Indications for the procedure include
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go a second pulmonary metastasectomy, 5-year sur-
vival was 44% and 10-year survival was 29%. Further
analysis of this subgroup is not available.
We sought to address the potential role for repeated
application of surgical resection of thoracic metastases
for those unusual patients in whom the recurrence is
restricted to the chest. Specifically, is there a limit to
the number of attempts of thoracic metastasectomy
conferring benefit on the patient? What factors estab-
lish that limit? What advice can be given to a patient
facing a third or fourth attempt at thoracic metastasec-
tomy in regard to risk and expected benefit?
Since 1988, the Division of Thoracic Surgery at
Brigham and Women’s Hospital has offered surgical
resection of pulmonary metastases for those highly
selected patients who continue to meet the basic crite-
ria, regardless of the number of previous attempts.
Repeat metastasectomy was offered to those patients
with adequate cardiopulmonary reserve who had no
cancer in any other sites and in whom an operation was
technically feasible. Analysis of this cohort is used to
address the aforementioned questions.
Patients and methods
Standardized data collection forms are prospectively com-
pleted for all patients evaluated by the Division of Thoracic
Surgery at the Brigham and Women’s Hospital at preopera-
tive, operative, and postoperative interaction points. A full-
time thoracic surgical nurse/data manager compiles them into
a computerized database. Standard preoperative data include
spirometry, exercise oximetry, smoking history, and
Karnofsky performance scale. Operative data include type of
operation, surgical incisions, number and location of speci-
mens, and intraoperative complications. Postoperative data
include length of hospital stay and postoperative morbidity.
To be included in this series, the patient had to have had a
repeat (second to sixth) metastasectomy within the past 10
years, independent of the time of the previous metastasecto-
my and primary resection attempts. Patients who had 1 or
more metastasectomies and/or primary resection at other
institutions more than 10 years ago and who then had a repeat
effort to remove all intrathoracic metastases at our institution
were included. No patients were excluded who had a repeat
metastasectomy attempt within the past 10 years. 
Indications for attempted repeat metastasectomy included
previous resection and ongoing control of the primary site,
absence of extrathoracic metastases at the time of considering
repeat thoracic surgery, and adequate cardiopulmonary
reserve as estimated by a predicted postoperative forced expi-
ratory volume in 1 second of greater than 800 mL and a
myocardial ejection fraction of greater than 30%. 
Resections of pulmonary metastases by video-assisted tho-
racic surgery (VATS) techniques have been performed by our
group when considered technically feasible by the operating
surgeon. As our experience with the technique has grown, we
have no longer considered a repeat thoracic surgical proce-
dure on a previously treated hemithorax as a contraindication.
However, adhesions might preclude a VATS approach and
lead to a conversion to open thoracotomy. When considering
a VATS approach to metastasectomy, we obtain a high-reso-
lution spiral computed tomographic (CT) scan to detect addi-
tional occult metastases. If all the nodules targeted for metas-
tasectomy are physically located where they can be removed
with a VATS technique, we generally choose to start explo-
ration with a thoracoscope. If the nodule is found to be unre-
sectable with a safe margin by a VATS technique, we convert
to a thoracotomy. We did not prospectively collect data on the
VATS conversion rate.
Staged thoracotomies up to 8 weeks apart for bilateral dis-
ease were considered a single attempt to locally control dis-
ease within the lungs (ie, a single repeat metastasectomy). A
repeat attempt was defined as an additional operation to
remove all recurrent cancer after a disease-free interval fol-
lowing the last surgical procedure. This did not include any
operations that excised only benign nodules. Patients were
considered to have unresectable disease if there was evidence
of untreatable extrathoracic metastases when an additional
thoracic operation was being considered, inadequate car-
diopulmonary reserve, or technical inability to remove the
recurrent disease. An incomplete resection was defined as an
operation that did not remove all known tumor or one that left
positive microscopic margins. 
Operative data included the type of incision used, number
of metastases removed, size of the largest metastases
removed, magnitude of pulmonary resection (wedge versus
lobe), location of metastases, and reasons for inability to
remove all tumor. Operative mortality included all in-hospital
deaths and deaths after discharge if they occurred within the
first 30 days postoperatively.
The surgical nurse/data manager collected postoperative
morbidity data on a daily basis. Over 100 precoded, adverse
events were tracked by reviewing the inpatient record and
interviewing resident, nursing, and attending staff. Com-
plications were recorded in a prospective fashion and
reviewed at a weekly quality assurance meeting of the divi-
sion. Postoperative length of stay, final pathology results, and
mortality were also recorded.
Follow-up was performed at postoperative clinic visits 1
week and 6 weeks after surgery. A repeat chest CT scan was
generally performed 4 months after surgery and repeated
every 4 months for the first 2 years, followed by every 6
months for the next 5 years. Radiographic evidence of recur-
rent disease was frequently re-evaluated with a repeat spiral
chest CT scan in 6 to 12 weeks to judge the rate of progres-
sion and to look for additional signs of recurrence before
additional surgery. Ninety-eight percent of survival data were
actualized to October 1998.
Descriptive statistics included median, mean, and standard
deviation. Univariate analysis of demographic variables
between groups was performed with the Fisher exact test.
There was a single case of repeat metastasectomy for
melanoma. This case was not added to any of the other 3 his-
tologic groups for univariate or multivariate analysis.
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Multivariate analysis of patient variables associated with sur-
vival was performed by Cox proportional hazards model.
Survival curves were generated by Kaplan-Meier estimates. 
To analyze the influence of antecedent history on the out-
come of each repeated attempt at metastasectomy, we iden-
tified 4 separate “states” in which each patient could poten-
tially dwell after a repeat metastasectomy: (1) no clinical
evidence of recurrent disease, (2) recurrent disease
amenable to repeat surgical metastasectomy, (3) recurrent
disease not amenable to additional surgery or unresectable,
and (4) death. We further identified the first 2 states (no
clinical evidence of disease and recurrence amenable to
additional surgery) as desirable states and the latter 2
(unresectable and death) as undesirable states. By this def-
inition, all patients could potentially pass from a desirable
state to an undesirable state, but no patient could pass back
to a desirable state once they had reached unresectability or
death. The denominator of each strata (metastasectomy
attempt) is the number of patients in whom treatment failed
at the previous stratum. 
This stratification allowed us to perform sequential multi-
variate Cox proportional hazards models to examine the risk
of passing to an undesirable state as a function of the number
of previous metastasectomy attempts. This allows the time
spent within each stratum to be a continuous variable and the
risk of progressing to an undesirable state estimated for those
at risk in the time interval. Average baseline hazards were cal-
culated for each stratum based on the model. The survival
curves for those remaining amenable to additional surgery
were compared with those progressing to 1 of the 2 undesir-
able states with the log-rank test adjusted for the metastasec-
tomy strata.12 The appendix contains a description of the
models and variables used for the data analysis.
Results
Fifty-four patients had a repeat thoracic metastasec-
tomy with curative intent between July 1988 and
September 1998. The number of patients represents
14.6% of the 369 patients who underwent any type of
thoracic metastasectomy during the same time period.
Thirty-three of the patients undergoing repeat metasta-
sectomy were male (61%) and 21 were female. The
median age was 54 years, with a range from 22 to 76
years.
All 54 patients had at least 2 thoracic metastasec-
tomies in fulfillment of the entry criteria for this analy-
sis. Twenty-seven (50%) of the 54 patients had at least
3 thoracic metastasectomies, 12 (22%) had at least 4
thoracic metastasectomies, 6 (11%) had at least 5, and
1 patient had 6 thoracic metastasectomies. For statisti-
cal analysis, the 6 patients with 5 or more metastasec-
tomies were combined into a single group. 
As summarized in Table I, the metastatic cell type of
54 surgical specimens obtained at the first and second
thoracic metastasectomies included 29 (54%) carcino-
mas, 19 (35%) sarcomas, 5 (9%) germ cell tumors, and
1 (2%) melanoma. The 1 patient who underwent a sixth
thoracic metastasectomy had a germ cell tumor. There
was a significant statistical trend toward more sarco-
mas and germ cell tumors among patients undergoing
more than 3 thoracic metastasectomies (P = .0004). 
A total of 117 (76%) of the 154 operations performed
on this cohort involved only pulmonary parenchymal
resections, whereas 37 (24%) operations involved
extended thoracic metastasectomies including resec-
tions of diaphragm, pericardium, mediastinal nodes,
and chest wall. Fourteen operations (9%) combined
pulmonary parenchymal and extended thoracic resec-
tions. Twenty-three (15%) operations were extended
thoracic resections of mediastinal and/or chest wall
metastases without a pulmonary resection.
Surgical incisions included 1 clamshell incision, 5
staged bilateral thoracotomies, 17 median ster-
notomies, 94 unilateral thoracotomies, 7 thoracotomies
with en bloc chest wall resection, 4 bilateral VATS pro-
cedures, and 26 unilateral VATS procedures. The
largest resection performed was a pneumonectomy,
which occurred 5% of the time. Lobectomy was per-
formed 10% of the time, segmentectomy 4%, wedge
resection 62%, chest wall resection 12%, and a medi-
astinal resection 7%. 
Table I summarizes the important demographic vari-
ables of the 54 patients grouped by the maximum num-
ber of metastasectomies. The increase in the number of
men and the decrease in age at both the primary proce-
dure and current procedure of the group undergoing 5
or 6 metastasectomies reflects the dominance of germ
cell histologic type (77% within this group). Further-
more, the increase in the size of the largest metastasis
resected likely reflects a willingness to resect larger
recurrences in younger patients. There was no differ-
ence in the use of adjuvant therapy for the primary
tumor as a function of increasing attempts to perform
thoracic metastasectomies, but there appeared to be a
trend toward increasing use of adjuvant therapy with
increasing attempts at surgery. This trend did not reach
statistical significance. There was likewise no differ-
ence in the mean disease-free interval from the last pro-
cedure, the median number of metastases removed, the
size of the largest metastasis removed, nor the use of
wedge resection alone. 
A VATS technique was used in 11 of the primary
metastasectomies, with an average of 1.6 nodules
(range 1-4 nodules) being removed. When these 11
patients had a repeat metastasectomy, 4 had a repeat
ipsilateral VATS resection, 3 had an ipsilateral thora-
cotomy, 3 had a contralateral thoracotomy, and 1 had a
contralateral VATS resection. 
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Fourteen patients had a VATS resection at the second
metastasectomy, with an average of 1.5 nodules (range
1-6 nodules) being removed. Four patients had a VATS
resection at the third metastasectomy, with an average
of 1.5 nodules (range 1-2) being removed. One patient
had a VATS resection at the fourth metastasectomy,
with 2 nodules being removed. Of the 21 patients hav-
ing a VATS resection at the second or greater metasta-
sectomy, 7 (33%) had had previous ipsilateral VATS
resections, 5 (24%) had had previous ipsilateral open
resections, and 43% had had only contralateral proce-
dures. The largest nodule removed at the time of VATS
resection was an average of 1.3 cm (range 0.2-4.5 cm).
Thirty-seven percent of these patients received no
adjuvant therapy. Twenty percent received chemothera-
py only, 13% received radiation only, and 30% received
a combination of radiation and chemotherapy.
The median number of metastases excised at each
operation was 1 for first metastasectomy (range 1-6), 1
for second (range 1-20), 2 for third (range 1-10), 2 for
fourth (range 1-9), and 2 for 5 or more metastasec-
tomies (range 1-8). No statistically significant differ-
ence existed among these groups.
The median size of the largest metastasis excised at
each operation was 1.7 cm for first metastasectomy
(range 0.2-15 cm), 2.4 cm for second (range 0.1-12
cm), 3.2 cm for third (range 0.2-12.5 cm), 2.9 cm for
fourth (range 1-18 cm), and 4.5 cm for fifth or more
metastasectomies (range 2-20 cm). Size of largest
metastasis was not a predictor of long-term survival.
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Table I. Cross-sectional characteristics of metastasectomy strata
Metastasectomy attempt
2 (n = 54) 3 (n = 27) 4 (n = 12) 5 (n = 6)
Male, n (%) 33 (61) 21 (78) 10 (83) 6 (100)
Age at this metastasectomy (median) 52.9 51.5 44.5 33
Age at primary metastasectomy (median) 47.7 44.8 34.6 27.8
Histologic type at this procedure, n (%)
Carcinoma 29 (54) 9 (33) 2 (17) 1 (17)
Sarcoma 19 (35) 14 (52) 6 (50) 1 (17)
Germ cell 5 (9) 4 (15) 4 (33) 4 (67)
Melanoma 1 (2) 0 0 0
Chemotherapy for primary, n (%) 14 (26) 8 (30) 5 (42) 5 (83)
Radiation therapy for primary, n (%) 16 (30) 9 (33) 5 (42) 2 (33)
Disease-free interval from last metastasectomy (mean ± SD) 21.3 ± 18 19.7 ± 23 28.3 ± 72 19.3 ± 17
No. metastases (median) 1.0 2.0 2.0 2.0
Size of largest metastasis, cm (median) 2.5 3.0 3.2 4.3
Wedge, n (%) 36 (67) 17 (63) 7 (58) 4 (67)
VATS, n (%) 16 (30) 4 (15) 1 (8) 0
Chemotherapy this metastasectomy, n (%) 10 (18) 5 (18) 4 (33) 1 (17)
Radiation therapy this metastasectomy, n (%) 4 (7) 5 (18) 3 (25) 2 (33)
Distribution of the cell type of the metastases removed within each group of metastasectomy attempt. There was a significant statistical trend toward more sarcomas
and germ cell tumors among patients undergoing more than 3 thoracic metastasectomies (P = .0004).
Table II. Hazard of progressing to an undesirable outcome as a function of metastasectomy attempt
Desirable Undesirable
No Resectable Unresectable HR of progressing
recurrence recurrence recurrence Death to undesirable
Total procedures n (%) n (%) n (%) n (%) Mean ± SD
Two 15 (27) 27 (50) 3 (6) 9 (17) 0.21 ± 0.16
Three 5 (19) 12 (44) 2 (7) 8 (30) 0.54 ± 0.35
Four 1 (8) 6 (50) 2 (17) 3 (25) 0.86 ± 0.19
Five or more 0 1 (17) 2 (33) 3 (50) 0.91 ± 0.14
Each metastasectomy attempt had 1 of 4 possible outcomes: No recurrence of disease to date, a temporary period of disease control followed by intrathoracic recur-
rence amenable to additional surgery to re-establish control within the chest, a temporary period of disease control followed by an unresectable recurrence, or death.
The former 2 states are considered “desirable” and the latter 2, “undesirable.” The number of patients in the state of recurrence amenable to more surgery became
the denominator of the next metastasectomy attempt. The hazard ratio (HR) of progressing to an undesirable outcome as a function of metastasectomy attempt is sum-
marized to the right of the table. 
A complete resection was obtained in 141 (91.6%) of
154 total operations. Of the 13 patients undergoing
incomplete resections, 7 had an additional operation
from 2 to 39 months later. Five of these 7 subsequent-
ly had a complete resection by way of a larger opera-
tion. The remaining 2 patients had an additional incom-
plete resection 12 and 13 months later.
Sequential follow-up to October 1998 was achieved
for 53 (98%) of the 54 patients. Median follow-up time
is 48 months, measuring from the day of the second
metastasectomy. Cumulative 5-year survival is 57%
from the time of the second metastasectomy. There
were no operative deaths. All late deaths occurred from
cancer. 
Table II summarizes the distribution of 4 possible
outcome states as a function of metastasectomy
attempts: no recurrence of disease to date, a temporary
period of disease control followed by intrathoracic
recurrence amenable to additional surgery to re-estab-
lish control within the chest, a temporary period of dis-
ease control followed by an unresectable recurrence, or
death. The former 2 states are considered “desirable”
and the latter 2, “undesirable.” The number of patients
in the state of recurrence amenable to more surgery
becomes the denominator of the next metastasectomy
attempt. The hazard ratio of progressing to an undesir-
able outcome as a function of metastasectomy attempt
is summarized to the right of the table. The probability
of progressing to unresectability or death after a repeat
metastasectomy increased from .21 after the second
attempt to .91 after the fifth attempt.
Of the 33 patients who have had an unresectable
recurrence, 18 (55%) lacked sufficient cardiopul-
monary reserve to undergo additional surgery, 11
(33%) had technically unresectable disease, and 4
(12%) had recurrences outside the thorax.
The 5-year survival from second metastasectomy
(model 1; see appendix) for those undergoing 2 proce-
dures is 59% (median greater than 60 months), 33% for
those undergoing 3 procedures (median 34.7 months),
and 38% for those undergoing 4 or more procedures
(median 45.6 months). All deaths are due to recurrent
unresectable cancer. The slope of decay of each survival
curve is similar, suggesting a similar biology of the unre-
sectable tumor between groups. Yet the re-establishment
of local control in the chest has extended survival for an
additional 1 to 3 years for those patients fortunate
enough to undergo a third or fourth metastasectomy. 
When comparing those patients who progressed to an
undesirable state with those who remained within a
desirable state, the Cox proportional hazards model
(model 2; see appendix) gives a hazard ratio of 3.8 (95%
confidence intervals: 1.1, 12.8) for the undesirable
cohort, meaning those patients progressing to an unre-
sectable recurrence are 3.8 times more likely to die. 
The above analysis is unable to differentiate whether
the increase in survival with additional procedures is due
to repeat surgery or to the patients being obligated to sur-
vive longer to experience a third or fourth procedure. 
The number of metastasectomy attempts does not
correlate with disease-free survival (model 3; see
appendix). Predictors of disease-free survival include
metastatic involvement of only the lung parenchyma
compared with extended resections involving the chest
wall or mediastinum (P = .003). Other predictor vari-
ables not associated with long-term survival are listed
in the appendix.
To determine whether thoracic disease tended to
recur more frequently and sooner after each procedure,
we constructed a new model (model 4; see appendix).
The hazard ratios for recurrence increase dramatically
with each procedure, from 3.2 after 3 metastasectomies
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Table III.  Recurrence after each procedure
Previous metastasectomies HR (95% CI)
Two Reference group
Three 3.2 (1.2, 8.6)
Four 5.5 (1.8, 17.4)
Five or more 12.9 (4.3, 39)
Hazards of developing recurrence as a function of the number of previous
metastasectomies. The hazard ratios (HR) significantly increase after each
additional procedure. CI, Confidence intervals.
Table IV. Death after each procedure
Previous metastasectomies HR (95% CI)
Two Reference group
Three 3.0 (1.2, 7.8)
Four 2.6 (0.7, 9.7)
Five or more 7.1 (2.1, 24)
Hazards of death as a function of the number of previous metastasectomies.
Survival remains stable until the fifth procedure, when hazard ratios (HR) sig-
nificantly increase. CI, Confidence intervals.
Table V.  Progression to an undesirable state after
each procedure
Previous metastasectomies HR (95% CI)
Two Reference group
Three 2.7 (1.2, 6.3)
Four 3.4 (1.2, 9.9)
Five or more 8.5 (3.0, 24)
Hazards of progression to an undesirable state (ie, unresectability or death) as
a function of the number of previous metastasectomies. Rate of progression
slightly increases after the third and fourth procedures and significantly
increases after the fifth attempt. HR, Hazard ratios; CI, confidence intervals.
to 12.9 after 5 or more procedures (Table III). Although
recurrence increases with each procedure, survival
(model 5; see appendix) is fairly stable until the fifth or
more procedure (Table IV, Fig 1). 
Rate of progression to an undesirable state (ie, unre-
sectable recurrence or death) (model 6; see appendix)
slowly increases until the fifth or more procedure
(Table V). Once patients were considered to have unre-
sectable disease, survival was independent of the num-
ber of antecedent procedures (model 7; see appendix).
The lower curve in Fig 2 shows the survival curve for
these patients from the time of recognized unresectable
recurrence. Median survival was only 8 months, with a
2-year survival of 19%. The upper curve in Fig 2
depicts the overall survival of the cohort, with a 5-year
survival of 57%. The advantage conferred by repeat
metastasectomies lies somewhere between these 2
curves.
Discussion
The value of an aggressive surgical approach for
patients with recurrence confined to the thorax despite
previous metastasectomy was intuitive but not previ-
ously quantified. All patients within this study group
met previously established criteria including control of
all extrathoracic disease, adequate cardiopulmonary
reserve, and a technically feasible operation to remove
all recognized disease. The highly selected group pre-
sented here enjoyed a cumulative 57% 5-year survival
through repeated operations to remove local recur-
rences confined to the chest. This benchmark compares
favorably with the 30% to 48% cumulative 5-year sur-
vival for initial thoracic metastasectomy previously
reported by numerous authors.1-3,8,13-15 Furthermore,
there was a correlation between preserved intrathoracic
local control and 5-year survival. Once local control
had been lost, further survival fell dramatically to a
median of 8 months and a 2-year survival of 19%,
regardless of the number of previous procedures. 
The re-establishment of local control with multiple
metastasectomy attempts contributed to extended sur-
vival. This confirms similar findings in large series.1,2
The median survival of 8 months for patients with
unresectable recurrence correlates with previous obser-
vations that patients with incomplete resections or
unresectable disease have median survivals of 6 to 12
months.2,4 The salvage rate of 5 of 13 incomplete resec-
tions with additional adjuvant therapy and surgery is
encouraging. 
Fourteen percent of our patients had extended
intrathoracic resections, including mediastinal nodes,
pericardium, diaphragm, and chest wall. Other authors
have noted satisfactory results with similar extended
resections.3,8,16 Although the need for an extended
resection was a negative prognostic predictor of long-
term clinical disease-free survival compared with lung
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Fig 1. Kaplan-Meier survival curves from the time of the last metastasectomy for patients undergoing 2, 3, 4, or 5
or more procedures (model 5; see appendix). Patients undergoing several procedures are included in several curves.
All deaths are due to cancer. The slopes of decay for the survival curves are fairly similar to each other until patients
undergo their fifth procedure (see Table IV). The advantage of repeat metastasectomy in terms of survival can be
thought of as the additional time that patients have had before undergoing the specific procedure that places them
in each curve. 
resections alone, we do not believe it should be regard-
ed as a contraindication to surgery since this subgroup
enjoyed a 5-year survival of 30% (median 47 months).
The percentage of patients undergoing repeat
metastasectomy in this cohort corresponds well with
the International Registry data of 5206 patients. In
that report, 15% of patients underwent a second
metastasectomy, 4% underwent a third, and 1% had 4
or more with a maximum of 7 metastasectomies.11
However, the survival of our selected group is better
than that of the reported survival in Pastorino’s
report,11 which was only 36% at 5 years and 26% at
10 years with a median of 35 months. This difference
may be due to the number of germ cell tumors within
our group or to the improved predictive power of their
larger, multi-institutional registry. Alternatively, this
may reflect a benefit of improved survival and local
control provided by repeated operations for thoracic
recurrence.
A similar cohort to our study group was reported by
Robert and associates.10 Of 276 patients undergoing
metastasectomy, 63 had a second-stage metastasecto-
my, 12 a third-stage, and 2 patients a fourth-stage.
Median follow-up of this cohort was 38 months, with a
2-year survival of 69% and a 5-year survival of 48%.
The association between preservation of intrathoracic
local control and survival was not tested, but the sur-
vival curves for patients having first- and second-stage
metastasectomy appear similar to each other. Our
analysis combined with this previous report suggests
that each successful metastasectomy re-establishes the
probability for long-term survival by returning the
patient to a clinical local control state.
The patients within this cohort were carefully select-
ed. The 92% complete resection rate compares favor-
ably with 2 previous reports of 85%2,17 and likely
reflects the careful selection of patients with resectable
disease for additional attempts at metastasectomy.
Most authors agree that surgery is indicated if it is tech-
nically feasible to remove all tumor while preserving
adequate cardiopulmonary function.12,18 We would
extend the indications to include those rare patients
who have a recurrence confined to the thorax, indepen-
dent of the number of previous surgical excisions. On
the other hand, the probability of benefiting from a
repeated attempt at thoracic metastasectomy diminish-
es after each previous operation. Additional attempts
should be carefully considered.
Chest recurrence increases after each additional
metastasectomy. These results suggest that either the
tumor biology is changing or the host-tumor interaction
begins to favor the tumor. However, survival is rela-
tively stable until the fifth procedure. This “stability” of
survival curves irrespective of the increase in recur-
rence rates may be due to the re-establishment of local
control in the chest.
Some authors remain skeptical about the value of tho-
racic metastasectomy.6,19 These authors point out that the
larger series are heterogeneous populations with mixed
histologic types and mixed doubling times. Several series
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Fig 2. Kaplan-Meier survival curves providing limits for prolongation of survival with repeat metastasectomy. The
lower curve depicts survival of patients once they have a recurrence not amenable to further surgery. Median sur-
vival is 8 months with a 2-year survival of 19% after the disease is declared unresectable. The upper curve shows
the overall survival for the cohort from the time of the second procedure with a 5-year survival of 57%. The advan-
tage conferred by repeat metastasectomy, in terms of survival, lies somewhere between both curves.
have correlated the best long-term survival with extended
disease-free interval12 or long tumor doubling times.
They argue that patients with a long tumor doubling time,
smaller tumor burden, and favorable histologic type will
do well whether they have a metastasectomy or not. If
this population makes up 30% to 40% of a given series,
these selection factors may translate into a 30% 5-year
survival without any benefit from surgery. These criti-
cisms have generally been put to rest by modern studies
that have demonstrated a survival advantage of surgery
compared with nonsurgical treatment.1,20
Our analysis argues against their point of view
because the subgroup that eventually lost intrathoracic
local control serves as its own control. Before the unre-
sectable recurrence, these patients had a median sur-
vival of 48 months. Expected survival drops to 8
months after the recurrence that can no longer be
removed. Furthermore, we believe the 57% cumulative
5-year survival of our entire study group (twice that of
previous reports) is due to the prolongation of clinical
disease-free status for as long as possible.
Other authors have failed to find a relationship
between long-term survival and the number of metas-
tases removed, disease-free interval, tumor doubling
time, age, sex, location, diameter of metastases, pre-
vious chemotherapy, and extent of resection as long as
a complete resection was achieved.2,3,5,7,8,15 The asso-
ciation of these variables with disease-free survival
does not appear to be as strong as the association
between survival and complete resection.7,18
One cannot hope to use a highly selected group to
conclusively prove the value of repeat metastasectomy.
However, this initial analysis is encouraging and seems
to justify repeat metastasectomy for carefully selected
patients. Part of this selection includes the repetition of
imaging studies 6 weeks after documenting a recur-
rence. Patients with rapidly progressive disease or the
development of numerous additional occult metastases
would not have been offered repeat metastasectomy.
Further work is required to understand the value of
repeat surgery for this biologically unique group of
patients who continue to have recurrences but only
within the chest. Data on similar subgroups of patients
offered repeat metastasectomy should be sought from
larger series of patients, including The International
Registry of Lung Metastases. Furthermore, new treat-
ment options are becoming available that might alter
the need for additional surgery in the future. These
include new adjuvant agents, including angiostatin
agents that might alter the thoracic “soil” which facili-
tates the growth of these malignant seeds. Stereotactic
radiation therapy for the chest is currently offered in a
handful of centers and may become more universally
applied. Finally, spiral CT scans and positron emission
tomographic scanning may assist in more accurately
judging the extent of small metastatic disease within
the chest and facilitate surgical metastasectomy.
At present, we feel justified in offering an aggressive
surgical approach to this minority of patients with
recurrent disease confined only to the thorax. Few
patients will meet these criteria. Once recurrent disease
is recognized, a careful evaluation of heart and lung
function should be undertaken. Extrathoracic disease
should be sought. The imaging studies should be
repeated in 6 weeks to exclude rapidly progressive dis-
ease and allow additional occult metastases to manifest
themselves. However, if the patient has sufficient car-
diopulmonary reserve and removal of all visualized
disease remains technically feasible, repeat surgical
metastasectomy should be offered.
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Appendix: Cox proportional hazards models used for the analysis of sequential metastasectomies
Model 1. Survival from second metastasectomy by number of procedures
Time zero: Date of second metastasectomy
Outcome(s): Death
Censored event(s): End of follow-up
Strata: Number of metastasectomies performed in each patient
Model 2. Survival from second metastasectomy by attainment of 
undesirable state
Time zero: Date of second metastasectomy
Outcome(s): Death
Censored event(s): End of follow-up
Strata: Desirability state
Reference group: Patients that remained in desirable state
Model 3. Disease-free survival after each procedure
Time zero: Date of last metastasectomy
Outcome(s): Death, recurrence
Censored event(s): End of follow-up
Strata: Procedure (metastasectomy)
Reference group: Second metastasectomy
*Patients with several procedures are included in several strata 
Model 4. Time to recurrence after each procedure
Time zero: Date of last metastasectomy
Outcome(s): Recurrence
Censored event(s): End of follow-up, death (without recurrence)
Strata: Procedure (metastasectomy)
Reference group: Second metastasectomy
*Patients with several procedures are included in several strata
Model 5. Survival after each procedure
Time zero: Date of last metastasectomy
Outcome(s): Death
Censored event(s): End of follow-up, going to next procedure
Strata: Procedure (metastasectomy)
Reference group: Second metastasectomy
*Patients with several procedures are included in several strata
Model 6. Rate of transition to an undesirable state (unresectability 
or death)
Time zero: Date of last metastasectomy
Outcome(s): Unresectable metastasis, death
Censored event(s): End of follow-up, going to next procedure
Strata: Procedure (metastasectomy)
Reference group: Second metastasectomy
*Patients with several procedures are included in several strata
Model 7. Survival after unresectability
Time zero: Date of claimed unresectability
Outcome(s): Death
Censored event(s): End of follow-up
Strata: Number of metastasectomies performed in each patient
Reference group: Patients with 2 metastasectomies
*Only patients with unresectable disease (n = 27) were included
Other variables included in the models and found not to be associated with survival or recurrence were sex, histology, disease-free intervals, history of chemothera-
py or radiation therapy for the primary tumor, number and size of metastases resected at current metastasectomy, site of disease, wedge versus larger resections, com-
pleteness of resection, use of VATS incision, and history of chemotherapy or radiation therapy for the current metastasectomy.
Discussion
Dr Richard Fosburg (Del Mar, Calif). Dr Jaklitsch has
described the outcome of 54 highly selected patients who
underwent 154 operations in a 10-year interval at one institu-
tion. One half of these patients underwent a third metastasec-
tomy, and the authors conclude that subsequent metastasec-
tomies may not be warranted. This subset represents
approximately 15% of all patients undergoing metastasecto-
my during the time frame, and the authors have provided us
with 3 statistical predictors of survival.
I have trouble accepting the idea that metastasectomy is
preserving control, rather than achieving control, but that can
be discussed later.
Dr Jaklitsch, your predictors are thoracic control, the need
for only 2 metastasectomies, and sustained absence of recur-
rent disease. From 1965 to the present, more than 450 articles
on pulmonary metastasectomy have been published. That
may be a bellwether that we have trouble determining what to
do with this particular problem. Interestingly, in 1998 and
1999, a paper on this subject has been presented at the meet-
ings of The American Association for Thoracic Surgery, The
Society of Thoracic Surgeons, and The Western Thoracic
Surgical Association. In 1947, John Alexander and Cameron
Haight were the first to attempt to establish criteria for pul-
monary resection. They had only a chest radiograph, and their
dilemma was that they did not know whether a tumor appear-
ing in the lung was a new primary or a metastasis. Therefore,
they believed it reasonable to operate on all of them. The set-
ting has changed. Now, 50 years later, we have the outcome
of a pulmonary metastasectomy registry, which was begun in
1991, and you have referred to that registry. The contributors
to the registry defined certain categories to use as their prog-
nostic groups as well, and Pastorino, who was writing for the
committee, had accrued 5206 cases and affirmed that com-
plete removal of all metastatic deposits was associated with
long-term survival. Therefore, we do have an objective.
In the groupings that the registry created, it was important
that resectability always be present if prognosis was to be
accurate. The absence of resectability is basically what
determines whether you carry on. All retrospective analyses
of this particular issue are characterized by a very similar
fault, and that is that the true extent of disease is not known.
Consequently, I think that the future will portend that we
will do much better in understanding which candidates
should undergo this procedure. I am referring to the evolu-
tion of positron emission tomography, using 18-fluo-
rodeoxyglucose as one method of identifying other metas-
tases. In 1998, the Health Care Financing Administration
approved positron emission tomographic scanning for eval-
uation of metastatic disease in lung cancer, and beginning
July 1, 1999, they extended the use of positron emission
tomographic scanning for malignant melanoma, lymphoma,
and colorectal cancer. At least we are moving in the right
direction. Old agents such as technetium 99 will be replaced
by newer agents, among which are 18-fluorothymidine,
F18-tagged sodium fluoride, and labeled markers like car-
cinogenic embryonic antigen. Consequently, I believe the
future is going to be different. The next analysis of this pro-
cedure may give us greater insight as to how to best handle
metastases.
You indicated that you grouped those staged patients as 1
operation even though they may have had multiple operations
to achieve clearance. Did any of those patients who were
staged in the 3-month interval have new lesions develop dur-
ing the interval between the operations?
Dr Jaklitsch. No. Only about 5 patients had a staged tho-
racotomy approach, about 11% of the entire group, and none
of them had new metastases within the interval between oper-
ations. We do routinely repeat the CT scan before the second
thoracotomy. 
Dr Fosburg. The Memorial people have told us that the
best way to determine a pulmonary metastasis is palpation by
the operating surgeon. They say that many lesions are missed.
That brings up the issue of how and when we do scans, at
what level we do cuts, and what size lesions we are detecting.
You indicated that VATS had been used in certain patients.
Did any of the patients undergoing VATS also have further
recurrences?
Dr Jaklitsch. Yes. The VATS operations cluster at the sec-
ond and the third attempts, so quite a number of those proce-
dures were followed by recurrence. We tested the use of a
VATS incision on univariate analysis to see whether that was
a predictor of recurrence and disease-free status and found no
association.
This is an area of interest throughout the country, and many
thoracic surgeons are being polarized regarding whether or
not VATS is an appropriate operation to perform for metasta-
sectomy. On one hand are McCormick and Martini’s data,
which show that about 43% of patients have undetected
metastases that can be found at open thoracotomy. On the
other hand is Putnam and Roth’s information that the median
sternotomy versus unilateral thoracotomy had no difference
in ultimate survival of the patient. Their information suggests
that lesions that are too occult to be detected radiographical-
ly, but can only be palpated by the surgeon’s hand, may not
be clinically important. I hope this area will be answered by
the current Cancer and Leukemia Group B trial of VATS
metastasectomy versus open thoracotomy, sponsored by the
National Cancer Institute.
Dr Fosburg. In those patients who were identified to have
a recurrence, you indicated that a helical CT scan was done
generally within 6 weeks. Your data indicate that the median
interval between the second and third procedures was about
12 months. Do you think 6 weeks is appropriate timing for
the CT scan? Are you comfortable with that short interval to
look at a process that seems to be extended over a longer
interval?
Dr Jaklitsch. That is a very valid criticism. We have come
to the realization that we are never free from the issue of
recurrence in metastasectomy patients. In patients who we
believe have no evidence of disease, we repeat the CT scan
about 3 times a year, or every 4 months. It usually takes more
than the first recurrence detected on the CT scan to convince
us to reoperate. We usually repeat that CT scan between 6
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weeks and 3 months to judge the rate of progression. Now,
many of the patients whose disease has become technically
unresectable have had a blossoming during that interval, with
the development of numerous lesions.
Dr Fosburg. The median size of the largest metastasis
excised at each subsequent surgical procedure sequentially
increased, as might be expected from a logarithmic growth
curve. Were calculations of tumor doubling times used in any
way to assist in your decisions? 
Dr Jaklitsch. No. We do not prospectively use tumor dou-
bling time. We tried to recreate it for this manuscript, but we
were only able to generate it for about 25% of our patients. 
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